- The United States Food and Drug Administration (FDA) has granted approval under the ‘National Priority Voucher Program’.
- Development: By Regeneron Pharmaceuticals.
- This therapy is approved for the treatment of a specific type of hearing loss caused by mutations in the OTOF gene.
- This gene codes for a protein called Otoferlin.
